A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2018

At a glance

  • Drugs Cemiplimab (Primary) ; Ipilimumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EMPOWER-lung 4
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
    • 13 Sep 2018 Planned number of patients changed from 201 to 252.
    • 13 Sep 2018 Planned End Date changed from 17 Nov 2021 to 26 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top